ASP9521, a novel, selective, orally bioavailable AKR1C3 (type 5, 17β-hydroxysteroid dehydrogenase) inhibitor: In vitro and in vivo characterization.

被引：0
|
作者：
Kikuchi, Aya
Enjo, Kentaro
Furutani, Takashi
Azami, Hidenori
Nimi, Tatsuya
Kuromitsu, Sadao
Kamiyma, Yoshiteru
机构：
[1] Astellas Pharma US Inc, Ibaraki, Japan
[2] Astellas Pharma US Inc, Deerfield, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5046
引用
收藏
页数：1
相关论文
共 50 条
  • [1] In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3)
    Kikuchi, Aya
    Furutani, Takashi
    Azami, Hidenori
    Watanabe, Kazushi
    Niimi, Tatsuya
    Kamiyama, Yoshiteru
    Kuromitsu, Sadao
    Baskin-Bey, Edwina
    Heeringa, Marten
    Ouatas, Taoufik
    Enjo, Kentaro
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (05) : 860 - 870
  • [2] In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3)
    Aya Kikuchi
    Takashi Furutani
    Hidenori Azami
    Kazushi Watanabe
    Tatsuya Niimi
    Yoshiteru Kamiyama
    Sadao Kuromitsu
    Edwina Baskin-Bey
    Marten Heeringa
    Taoufik Ouatas
    Kentaro Enjo
    Investigational New Drugs, 2014, 32 : 860 - 870
  • [3] Discovery of ASP9521, a novel, potent, selective 17β-HSD5 inhibitor
    Watanabe, Kazushi
    Kakefuda, Akio
    Yasuda, Minoru
    Amano, Yasushi
    Enjo, Kentaro
    Kikuchi, Aya
    Furutani, Takashi
    Naritomi, Yoichi
    Otsuka, Yukio
    Okada, Minoru
    Ohta, Mitsuaki
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246
  • [4] Structure-function aspects and inhibitor design of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3)
    Penning, TM
    Burczynski, ME
    Jez, JM
    Lin, HK
    Ma, HC
    Moore, M
    Ratnam, K
    Palackal, N
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2001, 171 (1-2) : 137 - 149
  • [5] Screening baccharin analogs as selective inhibitors against type 5 17β-hydroxysteroid dehydrogenase (AKR1C3)
    Zang, Tianzhu
    Verma, Kshitij
    Chen, Mo
    Jin, Yi
    Trippier, Paul C.
    Penning, Trevor M.
    CHEMICO-BIOLOGICAL INTERACTIONS, 2015, 234 : 339 - 348
  • [6] Development of potent and selective baccharin analogs for the inhibition of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3)
    Zang, Tianzhu
    Verma, Kshitij
    Trippier, Paul
    Penning, Trevor
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
  • [7] Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): Overview and structural insights
    Byrns, Michael C.
    Jin, Yi
    Penning, Trevor M.
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2011, 125 (1-2): : 95 - 104
  • [8] Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase (AKR1C3)
    Flanagan, Jack U.
    Atwell, Graham J.
    Heinrich, Daniel M.
    Brooke, Darby G.
    Silva, Shevan
    Rigoreau, Laurent J. M.
    Trivier, Elisabeth
    Turnbull, Andrew P.
    Raynham, Tony
    Jamieson, Stephen M. F.
    Denny, William A.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2014, 22 (03) : 967 - 977
  • [9] Type 5 17β-Hydroxysteroid Dehydrogenase (AKR1C3) Contributes to Testosterone Production in the Adrenal Reticularis
    Nakamura, Yasuhiro
    Hornsby, Peter J.
    Casson, Peter
    Morimoto, Ryo
    Satoh, Fumitoshi
    Xing, Yewei
    Kennedy, Michael R.
    Sasano, Hironobu
    Rainey, William E.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (06): : 2192 - 2198
  • [10] Discovery of a bifunctional Type 5 17b-hydroxysteroid dehydrogenase (AKR1C3) inhibitor and androgen receptor antagonist
    Adeniji, Adegoke O.
    Twenter, Barry M.
    Winkler, Jeffrey D.
    Penning, Trevor M.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
12345